Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis

Chalmer, Thor Ameri; Buron, Mathias Due; Illés, Zsolt; Papp, Viktória; Theódórsdóttir, Ásta; Schäfer, Jakob; Hansen, Victoria; Asgari, Nasrin; Skejø, Pernille Bro; Jensen, Henrik Boye; Sørensen, Per Soelberg; Magyari, Melinda

doi:10.1136/jnnp-2019-321523

Cited by 16 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment effectiveness of Interferon‐β is not different in women and men (Magyari et al, 2014). Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis (Chalmer et al, 2020). Treatment escalation leads to fewer relapses compared with lateral switching to another moderately effective therapy (Chalmer et al, 2019).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Danish Multiple Sclerosis Registry

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objectives The Danish Multiple Sclerosis Registry is the oldest operative and nationwide MS registry. We present The Danish Multiple Sclerosis Registry with its history, data collection, scientific contribution, and national and international research collaboration. Materials and Methods Detailed description of data collection, completeness, quality optimizing procedures, funding, and legal, ethical and data protection issues are provided. Results The total number of registered cases with clinical isolated syndrome and multiple sclerosis since 1956 was by start of May 2020 30,023 of whom 16,515 cases were alive and residing in Denmark, giving a prevalence rate of about 284 per 100,000 population. The mean annual number of new cases receiving an MS diagnosis was 649 per year in the period 2010 to 2019. In total, 7,945 patients (48.1%) are receiving disease modifying therapy at the start of May 2020. Conclusions Multiple Sclerosis registers are becoming increasingly important, not only for epidemiological research but also by quantifying the burden of the disease for the patients and society and helping health care providers and regulators in their decisions. The Danish Multiple Sclerosis Registry has served as data source for a number of scientific publications including epidemiological studies on changes in incidence and mortality, cohort studies investigating risk factors for developing MS, comorbidities and socioeconomic outcomes in the MS population, and observational studies on effectiveness of disease modifying treatments outside the narrow realms of randomized clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

“…• Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis (Chalmer et al, 2020).…”

Section: Ms Cohort Observational Studiesmentioning

confidence: 99%

The Danish Multiple Sclerosis Registry

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…[14,15] A recent study of patients in Denmark demonstrated that a clinically stable disease course was associated with a reduced risk of losing income from salaries and disability pension compared with those that did not have a clinically stable disease course. [22] Studies in other therapeutic areas showed that simpler and less frequent dosing led to greater adherence than more frequent administration. [23][24][25] The current study is unique in that it provided primary data on the indirect costs of MS, which are not readily available and are not commonly evaluated, particularly in the US.…”

Section: Discussionmentioning

confidence: 99%

The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis

Hersh

Brook²,

Beren

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

Aim: Multiple sclerosis (MS) poses a substantial employer burden in medically related absenteeism and disability costs due to the chronic and debilitating nature of the disease. Although previous studies have evaluated relapse, nonadherence, discontinuation, and switching individually, little is known about their overall collective prevalence and implications in employees with MS treated with disease-modifying therapies (DMTs). This study evaluated the proportion of employees with MS with suboptimal DMT year-1 outcomes and to quantify the clinical and economic burden of suboptimal year-1 outcomes from a US employer perspective. Materials and Methods: Employees with MS were selected from the WorkPartners database. Eligibility criteria were: ≥2 MS diagnosis claims (ICD-9-CM 340.xx/ICD-10-CM G35) from 1/1/2010-3/31/2019, ≥1 once-/twice-daily oral or self-injectable DMT claim (first claim=index), continuous eligibility 6-months pre-/1-year post-index, no baseline DMT, and age 18-64 years. Suboptimal year-1 outcomes included: non-adherence (proportion of days covered <80%), discontinuation (gap >60 days), switch, or relapse (MS-related hospitalization, emergency room visit, or outpatient visit with corticosteroid). A two-part logistic-generalized linear model evaluated costs.

show abstract

“…Health care services should consider the benefits of an agile infusion service that supports continued employment and the psychological impact of nonemployment. 15,16 Thirty-six percent of the employed or studying respondents preferred infusion times after noon, in contrast to only 17% of those not working or studying. However, working and studying respondents are slightly less likely to prefer/consider home infusions.…”

Section: O N L I N E F I R S Tmentioning

confidence: 99%

Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders

Rath¹,

Campagna²,

Stankovich³

et al. 2020

International Journal of MS Care

View full text Add to dashboard Cite

Background: People with multiple sclerosis and neuroimmunologic disorders (herein referred to as patients) are increasingly treated with infusible monoclonal antibodies. This rise in demand has placed increased loads on current infusion services and mandates careful strategic planning. This study examined patient preferences for the timing and location of infusions and their association with demographic and disease variables to facilitate patient-focused strategic planning. Methods: Ninety-one patients receiving an infusible therapy at an infusion service during March 2019 were asked to complete a questionnaire exploring eight domains, including preferences for time of infusions and location of infusion centers. Potential access to home-based treatment was included as an option. Unstructured (free-text) feedback on current service was also obtained. Results: Eighty-three patients completed the survey (mean age, 42 years; 75% women). Infusions were predominantly natalizumab (66%) and ocrelizumab (25%). Of these patients, 71% were engaged in some form of work or study, and 83% of this group had to arrange time off from work or study to attend treatment. Seventy percent of patients would prefer their infusion before noon, and 60% would consider home-based infusions. Most used a car as their transport to the infusion service. Conclusions: These results suggest that patients are more likely to prefer infusible treatment in the morning and are open to home-based infusions. This study provides information for health services to target service delivery at peak preference times and consider alternate ways of delivering infusible treatments.

show abstract

Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis

Cited by 16 publications

References 41 publications

The Danish Multiple Sclerosis Registry

The Danish Multiple Sclerosis Registry

The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis

Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders

Contact Info

Product

Resources

About